期刊文献+

90例老年胃间质瘤患者手术治疗及预后分析 被引量:7

Clinicopathological Charactersistics and Prognostic Factors of 90 Erderly Patients with Gastric GIST
下载PDF
导出
摘要 目的分析老年胃间质瘤的临床特点,探讨影响其预后的临床因素。方法回顾性分析2000年1月2011年1月期间在中国医学科学院肿瘤医院接受手术治疗并经病理证实的90例老年胃间质瘤患者的临床资料,统计分析影响其预后的因素。结果 90例患者均接受手术切除,随访率87.0%。其1、3、5年总体生存率分别为79.7%、50.6%和32.9%;1、3、5年无进展生存率为75.9%、49.4%和32.9%。单因素分析影响老年胃间质瘤术后无疾病进展生存时间(PFS)和总生存时间(OS)的因素均为:肿瘤大小、肿瘤坏死、核分裂象和NIH危险度分级标准。结论老年胃间质瘤患者总体预后欠佳。肿瘤大小、肿瘤坏死、核分裂像和NIH危险度分级标准是影响老年胃间质瘤患者术后预后的危险因素。 Objective To analysis the clinical and pathological characteristics of gastrointestinal stromal tumors of the stomach in erderly patients and explore associated prognostic factors. Methods Ninety erderly gastric GISTs patients confirmed pathologically were ineluded from 2000 to 2011. Their clinical datas were retrospectively analyzed. Results The followup rate was 82. %. The overal survival (OS) of 1,3 and 5 years were 79.7% ,50.6% and 32.9% , respectively. The progression free survival (PFS) of 1,3 and 5 years were 75.9% ,49.4% and 32.9% , respectively. Single factor survival analysis showed that OS and PFS had significant association with tumor size, tumor necrosis, mitotic index and NIH risk group. Conclusion Elderly patients with gastric stromal tumor have poor prognosis than others. Tumor size, tumor necrosis, mitotic index and NIH risk group are potential prognositic factor of gastric GISTs.
出处 《医学研究杂志》 2013年第6期45-48,共4页 Journal of Medical Research
基金 吴阶平医学基金会临床科研专项基金资助项目(320675012622)
关键词 老年 胃间质瘤 外科手术 伊马替尼 预后 Elderly Gastrointestinal stromal tumors Surgical procedures Imatinib Prognosis
  • 相关文献

参考文献9

  • 1Reichardta P, Hogendoornb CW,Tamborinic E, et al. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgi- cal issues[ J]. Semin 0ncol,2009,36(4) :290 - 301.
  • 2Huang H,Liu YX,Zhan ZL,et al. Different sites and prognoses of gas- trointestinal stromal tumorsof the stomach: report of 187 cases [ J]. World J Surg,2010,34 : 1523 - 1533.
  • 3Joensuu H, Vehtari A, Riihimfiki J,et al. Risk of recurrence of gastro- intestinal stromal turnout after surgery : an analysls of pooled populatlon - based cohorts [ J ]. Lancet 0ncol,2012,13 ( 3 ) :265 - 274.
  • 4CAO Hui,ZHANG Yun,WANG Ming,SHEN Dan-ping,SHENG Zhi-yong,NI Xing-zhi,WU Zhi-yong,LIU Qiang,SHEN Yan-ying,SONG Yan-yan.Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease[J].Chinese Medical Journal,2010(2):131-136. 被引量:20
  • 5Chen YH, Liu KH, Yeh CN,et al. Laparoscopic resection of gastroin- testinal stromal tumors: safe, efficient, and comparable oncologic out- comes[J]. J Laparoendosc Adv Surg Tech A,2012,22(8) : 758 -763.
  • 6中国胃肠间质瘤诊断治疗专家共识(2011年版)[J].中华胃肠外科杂志,2012,15(3):301-307. 被引量:117
  • 7Dematteo R, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localized, primary gastrointestinal stromal tumours : a randomised, doable - blind, placebo - controlled trial [J]. Lancet, 2009,373 (9669) : 1097 - 1104.
  • 8Corless CL, Ballman KV, Antonesc UC, st al, Relation of tumor path- ologic and molecular features to outcome after surgical resection of lo- calized primary gastrointestinal stromal tumor(GIST) : result of the in- tergroup phase III trial ACOSOC Z9001 [ J]. J Clin Oncol, 2010,28 ( suppl 15 ) : 10006.
  • 9薛春燕,高伟,王雅杰.伊马替尼治疗胃肠道间质瘤58例疗效分析[J].医学研究杂志,2010,39(9):94-96. 被引量:2

二级参考文献60

  • 1王海江,杨新辉.甲磺酸伊马替尼治疗手术后复发和/或转移的胃肠道间质瘤的疗效分析[J].新疆医科大学学报,2008,31(12):1716-1717. 被引量:1
  • 2贺慧颖,方伟岗,钟镐镐,李燕,郑杰,杜娟,衡万杰,吴秉铨.165例胃肠道间质瘤中c-kit和PDGFRA基因突变的检测和临床诊断意义[J].中华病理学杂志,2006,35(5):262-266. 被引量:73
  • 3詹文华,王鹏志,邵永孚,伍晓汀,顾晋,李荣,万德森,丁克峰,师英强,于吉人,卢辉山,邹小明,毕建威,孙益红,陆云飞,陈道达,张信华.伊马替尼术后辅助治疗胃肠间质瘤的多中心前瞻性临床试验中期报告[J].中华胃肠外科杂志,2006,9(5):383-387. 被引量:85
  • 4张信华,何裕隆,詹文华,蔡世荣,张常华.胃肠间质瘤135例临床诊治分析[J].中华胃肠外科杂志,2007,10(1):17-20. 被引量:38
  • 5Mussi C, Ronellenfitsch U , Jakob J, et al. Post - imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Annals of Oncology, 2009,10 : 1093.
  • 6Eisenberg BL, Harris J, Blanke CD,et al. Phase Ⅱ trial of neoadjurant/adjuvant imatinib mesylatc (IM) for advanced primary and meta-static/recurrent operable gastrointestinal stromal tumor (GIST) : early results of RTOG 0132/ACRIN 6665. J Surg Oncol, 2009,99( 1 ) :42 -47.
  • 7E isenburg BL,Judson I. Surgery and imatinib in the management of GIST: Emerging approaches to adjuvant and neoadjuvant therapy. Annals of Surgical Oneoloy, 2004,11 (5) :465 - 475.
  • 8Miettinen M, Lasota J. Gastrointestinal stromal tumors definition, clinical,histological,immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch ,2001,438 ( 1 ) : 1.
  • 9Rankin C, Yon Mehren M, Blanke C, et al. Dose efect of imatinib in patients wi th metastatic GIST- Phase Ⅲ Sarcoma Group Study S0033. Proc Am Soc Clin Oncol, 2004,23:815.
  • 10Kikuchi H, Yamamoto M, Hiramatsu Y, et al. Effect of loss of heterozygosity of the c - kit gene on prognosis after hepatectomy for metastatic liver gastrointestinM stromal tumors. Cancer Sci ,2007 ,98 ( 11 ) : 1734 - 1739.

共引文献135

同被引文献34

引证文献7

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部